Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Idera Pharmaceuticals Inc.
DescriptionSynthetic oligonucleotide-based toll-like receptor 9 (TLR9) agonist
Molecular Target Toll-like receptor 9 (TLR9)
Mechanism of ActionToll-like receptor 9 (TLR9) agonist
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationMelanoma
Indication DetailsTreat metastatic melanoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today